Profil
Erin Boyer currently works at uniQure NV, as Chief People & Culture Officer from 2022.
Ms. Boyer also formerly worked at Obsidian Therapeutics, Inc., as Vice President-Human Resources, Alnylam Pharmaceuticals, Inc., as Head-Global Talent Strategy & Planning from 2017 to 2019, and Epizyme, Inc., as Chief People & Culture Officer from 2020 to 2022.
Ms. Boyer received her undergraduate degree from Macalester College.
Aktive Positionen von Erin Boyer
| Unternehmen | Position | Beginn |
|---|---|---|
| UNIQURE N.V. | Personalreferent | 01.04.2022 |
Ehemalige bekannte Positionen von Erin Boyer
| Unternehmen | Position | Ende |
|---|---|---|
| EPIZYME, INC. | Personalreferent | 01.04.2022 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.09.2019 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Personalreferent | - |
Ausbildung von Erin Boyer
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Macalester College
Macalester College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
uniQure NV
uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Health Technology |
















